

1 **Changing Diagnostic Testing Practices for Foodborne Pathogens, Foodborne Diseases**

2 **Active Surveillance Network, 2012–2019**

3
4 Logan C Ray: Division of Foodborne, Waterborne, and Environmental Diseases,
5 National Center for Emerging and Zoonotic Infectious Diseases, Centers
6 for Disease Control and Prevention, Atlanta, Georgia, United States.

7 Patricia M Griffin: Division of Foodborne, Waterborne, and Environmental Diseases,
8 National Center for Emerging and Zoonotic Infectious Diseases, Centers
9 for Disease Control and Prevention, Atlanta, Georgia, United States.

10 Katie Wymore: California Department of Public Health, Sacramento, California, United
11 States.

12 Elisha Wilson: Colorado Department of Public Health and Environment, 4300 Cherry
13 Creek Drive South, Denver, Colorado, United States.

14 Sharon Hurd: Connecticut Emerging Infections Program, 1 Church Street, New Haven,
15 Connecticut, United States.

16 Bethany LaClair: Georgia Department of Public Health, State of Georgia Building, 2
17 Peachtree St. Unit 5, Atlanta, Georgia, United States.

18 Sophia Wozny: Maryland Department of Health, 201 West Preston Street, Baltimore,
19 Maryland, United States.

20 Dana Eikmeier: Minnesota Department of Health, P.O. Box 64975 St. Paul, Minnesota,
21 United States.

22 Cyndy Nicholson: New Mexico Emerging Infections Program, 1601 Randolph SE, Suite
23 100S, Albuquerque, New Mexico, United States.

- 1 Kari Burzlaff: New York State Department of Health, 295 Main Street, Buffalo, New
2 York, United States.
- 3 Julie Hatch: Oregon Health Authority, 500 Summer Street, NE, E-20, Salem, Oregon,
4 United States.
- 5 Melissa Fankhauser: Tennessee Department of Health, Andrew Johnson Tower, 4th floor, 710
6 James Robertson Parkway, Nashville, Tennessee, United States.
- 7 Kristy Kubota: Association of Public Health Laboratories, 8515 Georgia Avenue, Suite
8 700, Silver Spring, Maryland, United States.
- 9 Jennifer Y. Huang: Division of Foodborne, Waterborne, and Environmental Diseases,
10 National Center for Emerging and Zoonotic Infectious Diseases, Centers
11 for Disease Control and Prevention, Atlanta, GA, United States
- 12 Aimee Geissler: Division of Foodborne, Waterborne, and Environmental Diseases,
13 National Center for Emerging and Zoonotic Infectious Diseases, Centers
14 for Disease Control and Prevention, Atlanta, GA, United States
- 15 Daniel C Payne: Division of Foodborne, Waterborne, and Environmental Diseases,
16 National Center for Emerging and Zoonotic Infectious Diseases, Centers
17 for Disease Control and Prevention, Atlanta, GA, United States
- 18 Danielle M Tack: Division of Foodborne, Waterborne, and Environmental Diseases,
19 National Center for Emerging and Zoonotic Infectious Diseases, Centers
20 for Disease Control and Prevention, Atlanta, GA, United States

21 **Keywords**

22 Foodborne illness, Foodborne Diseases Active Surveillance Network (FoodNet); Culture-
23 independent diagnostic test; Clinical laboratory testing practices; Reflex culture

Running Title

Diagnostic Testing for Foodborne Illness

Corresponding Author

Logan C Ray

Address: 1600 Clifton Road NE, Atlanta, GA, 30333, United States

Email: nbi9@cdc.gov

Phone: 404-718-5523

Alternate Corresponding Author

Danielle Tack

Address: 1600 Clifton Road NE, Atlanta, GA, 30333, United States

Email: dot7@cdc.gov

Phone: 404-718-3254

Abstract

Background. Pathogen detection has changed with increased use of culture-independent diagnostic tests (CIDTs). CIDTs do not yield isolates, which are necessary to detect outbreaks using whole-genome sequencing. The Foodborne Diseases Active Surveillance Network (FoodNet) monitors clinical laboratory testing practices to improve interpretation of surveillance data and assess availability of isolates. We describe changes in practices over eight years.

Methods. During 2012–2019, 10 FoodNet sites collected standardized data about practices in clinical laboratories (range, 664–723 laboratories) for select enteric pathogens. We assessed changes in practices.

Results. During 2012–2019, the percentage of laboratories that used only culture methods decreased, with largest declines for *Vibrio* (99% to 57%) and *Yersinia* (99% to 60%). During 2019, the percentage of laboratories using only CIDTs was highest for Shiga toxin-producing *Escherichia coli* (43%), *Campylobacter* (34%), and *Vibrio* (34%). From 2015 to 2019, the percentage of laboratories that performed reflex culture after a positive CIDT decreased, with largest declines for *Shigella* (75% to 42%) and *Salmonella* (70% to 38%). The percentage of laboratories that routinely submitted isolates to a public health laboratory decreased for all bacterial pathogens examined from 2015 to 2019.

Conclusions. By increasing use of CIDTs and decreasing reflex culture, clinical laboratories have transferred the burden of isolate recovery to public health laboratories. Until technologies allow for molecular subtyping directly from a patient specimen, state public health laboratories should consider updating enteric disease reporting requirements to include submission of isolates or specimens. Public health laboratories need resources for isolate recovery.

Background

Public health enteric infectious disease surveillance relies on clinical laboratories to submit isolates to state public health laboratories (SPHLs), which conduct whole-genome sequencing (WGS) to determine serotype, subtypes, and antimicrobial resistance, and use this information to detect and investigate outbreaks and sporadic cases. To detect these infections, laboratories are increasingly using culture-independent diagnostic tests (CIDTs), which do not yield isolates [1]. CIDTs include both nucleic acid amplification tests and antigen-based tests; some may offer increased sensitivity and provide results more rapidly than culture-based methods [2-4]. Syndromic panels are CIDTs that test for several pathogens; these offer the advantage of simultaneous testing for multiple bacterial, viral, and parasitic pathogens from a single specimen [5].

Complicating the interpretation of CIDT results is that sensitivity and specificity may differ among these assays, and that they might detect genetic material being shed following resolution of an infection rather than the live pathogen. Monitoring the adoption of changing laboratory testing practices can improve the understanding of enteric pathogen disease trends and burden, and can help in assessing the effectiveness of public health interventions [6].

The Foodborne Diseases Active Surveillance Network (FoodNet) is a collaboration among CDC, 10 state health departments, the U.S. Department of Agriculture's Food Safety and Inspection Service, and the Food and Drug Administration. FoodNet personnel conduct active, population-based surveillance for laboratory-diagnosed infections caused by *Campylobacter*, *Cryptosporidium* (until 2018), *Cyclospora*, *Listeria*, *Salmonella*, Shiga toxin-producing

Escherichia coli (STEC), *Shigella*, *Vibrio*, and *Yersinia* in 10 sites that account for approximately 15% of the U.S. population. In 2012, FoodNet staff began routinely asking clinical laboratories about diagnostic testing practices to provide context for disease surveillance. We describe changes in laboratory testing practices for pathogens captured by FoodNet surveillance from 2012 to 2019.

Methods

We collected standardized data elements for diagnostic laboratory practices specific to individual pathogens from hospital and reference laboratories by phone, email, and in person for the previous six months. Collection methods differed by site. For laboratories unresponsive to requests, we monitored for changes, and we assumed no change in laboratory practices from the previous year if we did not detect meaningful changes in reporting or in submission of specimens to the public health laboratory. Yearly metrics were not kept about laboratories unresponsive to requests; site personnel estimated that, on average, 5% (range 0–20%) were unresponsive to requests from year to year; most unresponsive laboratories did not test for enteric pathogens. State health officials submitted data to CDC based on pre-determined cycles. During 2012–2019, we conducted 13 noncontiguous cycles and analyzed data from the cycle that represented the most complete data for a specific year. We collected data for 2012, 2014–2017, and 2019 during April–August. For 2013 we collected data from December 2013 to February 2014, and data for 2018 from October 2018 to January 2019.

We collected data for *Campylobacter*, *Listeria*, *Salmonella*, STEC, *Shigella*, *Vibrio*, and *Yersinia* during all years, for *Cryptosporidium* data during 2012–2017, and for *Cyclospora* during 2018–

2019. We collected information on reflex culture and specimen submission practices for bacterial pathogens during 2015–2019. Data collected for *Listeria* were specific to its detection from blood and cerebrospinal fluid (CSF) specimens, and specific to stool specimens for all other pathogens. Practices for STEC were specific to culture methods to detect *E. coli* O157 on differential and selective media, and CIDs that detect Shiga toxin, O157 antigen, or their gene targets from stool or broth samples.

We defined syndromic panels as FDA-approved polymerase chain reaction-based panels with more than five targets designed to diagnose enteric infections. Most syndromic panels are designed to detect enteric pathogens from stool samples, with the exception of *Listeria*. *Listeria* is included in syndromic panels designed to identify pathogens typically isolated from CSF specimens and blood culture. Laboratory-developed tests (LDTs) are validated and controlled by a single laboratory, and often use commercially available reagents. Syndromic panel tests and LDTs are types of CIDT tests. We defined reflex culture as a culture done in response to a positive CIDT result.

We calculated rate ratios (RRs), 95% confidence intervals (CI), and p-values using SAS software version 9.4 (SAS Institute, Cary, North Carolina), and determined statistical significance ($p < 0.05$) using the 2-tailed Cochran-Mantel Haenszel χ^2 test. Percentages were calculated among non-missing values for pathogen-specific questions. Data are summarized by pathogen based on the number of laboratories that reported testing for the pathogen each year.

Results

During 2012–2019, sites received data annually from between 664 and 723 clinical laboratories serving the FoodNet catchment area. Some were in outpatient practice settings and hospitals; others were commercial reference laboratories. Most tested for *Campylobacter*, *Salmonella*, *Shigella*, and STEC (Table 1). Although testing practices varied by pathogen and year, most laboratories began adopting CIDs in 2015, most often PCR-based syndromic panels, and increased this use in subsequent years, expanding to all enteric pathogens (Figures 1 and 2). Increased use of CIDs corresponded with fewer laboratories attempting reflex culture, and fewer submissions of isolates to SPHLs; now many laboratories send broth or stool specimens to SPHLs (Figures 3 and 4).

Bacteria

Campylobacter

The number of laboratories using any method (culture-based, CIDT, or both) to test stool specimens for *Campylobacter* decreased significantly during 2019 compared with 2012 (RR = 0.82 [95% CI 0.71–0.94]) (Table 1). Among laboratories reporting test type, the percentage (and number) identifying *Campylobacter* by only culture methods decreased from 89% (402) in 2012 to 53% (202) in 2019, whereas those using CIDT alone or in combination with culture increased from 11% (49) in 2012 to 47% (181) in 2019 (Figure 1). During 2012, antigen tests (96%) were the most common type of CIDT reported (Figure 2). By 2019, 72% used syndromic panels. Few laboratories (22% [13]) performed reflex culture for *Campylobacter* during 2015 and that proportion had further decreased by 2019 (13% [24]) (Figure 3), despite more laboratories using CIDs. During 2015 to 2019, the percentage of laboratories routinely submitting *Campylobacter*

isolates to SPHLs decreased from 55% to 48%, and the percentage routinely submitting stool specimens increased from 9% to 33% (Figure 4).

Listeria

The number of laboratories able to test blood and CSF specimens for *Listeria* increased significantly during 2019 compared with 2012 (RR = 1.34 [95% CI 1.13–1.60]) (Table 1). During 2012, culture was the only method (Figure 1). During 2019, 29% (87) of laboratories reported using a CIDT with gene targets for *Listeria*. Most using CIDT (78% [63]) performed the test with culture, 10% (8) performed reflex culture following a positive CIDT, and 12% (10) used CIDT alone. Among laboratories that used CIDTs, 60% (49) used a syndromic panel designed to identify *Listeria* from blood culture specimens, 27% (22) used a syndromic panel designed to identify *Listeria* from CSF specimens, 10% (8) used both panel types, and 4% (3) used a laboratory-developed PCR test. During 2019, most laboratories (92% [274]) routinely submitted *Listeria* isolates to SPHLs, 3% (9) submitted only specimens, and 3% (10) reported not routinely submitting specimens or isolates.

Salmonella

The number of laboratories testing for *Salmonella* decreased significantly during 2019 compared with 2012 (RR = 0.81 [95% CI 0.71–0.93]) (Table 1). Among laboratories reporting test type, the percentage (and number) that identified *Salmonella* by only culture methods decreased from 98% (452) in 2012 to 64% (252) in 2019 whereas those using CIDT alone or in combination with culture methods increased from 2% (8) in 2012 to 36% (141) in 2019 (Figure 1). Among laboratories using CIDTs, the percentage using syndromic panels increased from 50% (3) in

2013 to 98% (137) in 2019. Most laboratories (70%) reported performing reflex culture during 2015; by 2019 this percentage had decreased to 38% (Figure 3). During 2015 to 2019, the percentage of laboratories routinely submitting *Salmonella* isolates to SPHLs decreased from 93% (330) to 81% (312), and the number routinely submitting stool specimens increased from 3% (10) to 34% (130) (Figure 4).

Shigella

The number of laboratories testing for *Shigella* decreased significantly during 2019 compared with 2012 (RR = 0.82 [95% CI 0.71–0.93]) (Table 1). Among laboratories reporting test type, the percentage (and number) that identified *Shigella* only by culture methods decreased from 98% (451) laboratories in 2012 to 64% (253) in 2019 whereas those using CIDI alone or in combination with culture methods increased from 2% (9) in 2012 to 36% (140) in 2019 (Figure 1). Among laboratories using CIDs, the percentage using syndromic panels increased from 60% (3) in 2013 to 98% (136) in 2019. Most laboratories (75%) reported performing reflex culture during 2015; during 2019, this decreased to 42% (Figure 3). During 2015 to 2019, the percentage of laboratories routinely submitting *Shigella* isolates to SPHLs decreased from 89% (314) to 79% (297), and the percentage routinely submitting stool specimens increased from 3% (9) to 34% (128) (Figure 4).

Shiga toxin-producing *Escherichia coli* (STEC)

The number of laboratories testing for STEC decreased significantly during 2019 compared with 2012 (RR = 0.83 [95% CI 0.72–0.96]) (Table 1). Among laboratories reporting test type, the percentage (and number) using culture methods alone to identify *Escherichia coli* O157

decreased from 45% (183) in 2012 to 14% (50) in 2019 whereas the percentage using CIDs in combination with culture methods to detect O157 or Shiga toxin increased from 37% (149) in 2012 to 43% (153) in 2019 (Figure 1). Laboratories using CIDs alone to detect O157 or Shiga toxin increased from 18% (74) in 2012 to 43% (152) in 2019. During 2012, most laboratories (99%) using CIDs reported using an antigen-based test, whereas during 2019 just 54% used antigen-based tests, 36% used syndromic panels, and 10% used both methods (Figure 2). During 2015 to 2019, the percentage of laboratories routinely submitting STEC isolates to SPHLs decreased from 64% (199) to 59% (205), and the percentage routinely submitting stool specimens increased from 16% (50) to 47% (162) (Figure 4).

Vibrio

From 2012 to 2019, the number of laboratories testing for *Vibrio* declined, but the change was not statistically significant (RR = 0.90 [95% CI 0.77–1.05]) (Table 1). Among laboratories reporting test type, the percentage (and number) that identified *Vibrio* by only culture methods decreased from 99% (319) in 2012 to 57% (164) in 2019, whereas the percentage using CIDs alone or in combination with culture methods increased from 1% (3) in 2012 to 43% (126) in 2019 (Figure 1). LDTs were the only type of CIDT reported during 2012–2014. By 2019, among laboratories using CIDs, 98% (124) used syndromic panels. Most laboratories (69%) did not perform reflex culture during 2015, and even fewer did during 2019 (26% [32]) (Figure 3). During 2015 to 2019, the percentage of laboratories routinely submitting *Vibrio* isolates to SPHLs decreased from 84% (215) to 71% (208), and the percentage routinely submitting stool specimens increased from 5% (12) to 41% (118) (Figure 4).

1 *Yersinia*

2 The number of laboratories testing for *Yersinia* decreased significantly during 2019 compared
 3 with 2012 (RR = 0.82 [95% CI 0.70–0.95]) (Table 1). Among laboratories reporting test type,
 4 the percentage (and number) that identified *Yersinia* by only culture methods decreased from
 5 99% (368) in 2012 to 60% (185) in 2019, whereas the percentage using CIDs alone or in
 6 combination with culture methods increased from 1% (2) in 2012 to 40% (122) in 2019 (Figure
 7 1). LDTs were the only type of CIDT reported during 2012–2014. By 2019, among the 122
 8 laboratories using CIDs, all used syndromic panels. Most (67%) did not perform reflex culture
 9 during 2015 and fewer (25%) did in 2019 (Figure 3). During 2015 to 2019, the percentage of
 10 laboratories routinely submitting *Yersinia* isolates to SPHLs decreased from 74% (208) to 72%
 11 (221), and the percentage routinely submitting stool specimens increased from 4% (11) to 37%
 12 (115) (Figure 4).

14 Parasites

15 *Cryptosporidium*

16 From 2012 to 2017, the last year FoodNet conducted surveillance for *Cryptosporidium*, the
 17 number of laboratories testing for it was similar. Most laboratories used a single test type during
 18 2012 (84% [211]) to 2017 (83% [221]). During 2012, the most common test used was an antigen
 19 test (70% [176]), followed by microscopy (45% [112]), and LDT (1% [2]). During 2017, antigen
 20 tests (62% [166]) and microscopy (31% [82]) were still the most common methods; however,
 21 26% (68) of laboratories reported using a PCR test. Use of syndromic panels increased from 1%
 22 (2) in 2013 to 24% (65) in 2017.

Cyclospora

During 2018 and 2019, the years *Cyclospora* data were collected, the number of laboratories testing for it was similar. On average, 62% of laboratories included tests for *Cyclospora* as part of routine enteric screening; the most common was a syndromic panel (87%). Among those not including *Cyclospora* in routine enteric screening, 10% of laboratories tested for it as part of ova and parasite testing, and 29% performed testing on clinician request; microscopy (63%) was the most common method used.

Discussion

The increased adoption of CIDs continues to alter the landscape of enteric pathogen detection and affect the interpretation of surveillance data. Beginning in 2013, following the introduction of FDA-approved syndromic panels, clinical laboratories began shifting from culture-based methods to CIDs for enteric bacterial and parasitic pathogens [7]. This shift largely correlates with an increase in infections diagnosed in FoodNet sites from 2013 through 2019 [1, 4, 8-11].

During 2012–2019, the number of clinical laboratories testing for enteric bacterial pathogens decreased, which might be due in part to laboratory mergers, acquisitions, and outsourcing [12]. Changes differed by pathogen. Decreases in clinical laboratory testing were greatest for *Campylobacter*, *Salmonella*, and *Shigella*, which had previously been the pathogens most often included in the routine culture of stool specimens [13]. Conversely, more laboratories indicated the ability to identify *Listeria* in blood and CSF samples in 2019 than in previous years.

1 Since 1995, clinical laboratories have increasingly adopted CIDs that detect Shiga toxins
2 produced by STEC [14]. Although *E. coli* O157 is readily identified by culture using differential
3 and selective media, there is not a selective agar for detecting non-O157 STEC strains. In 2011,
4 the rate of non-O157 infections surpassed that of O157 infections, and this was strongly
5 correlated with increases in CIDT use [15]. During 2012–2019, we observed that many
6 laboratories were discontinuing culture methods for STEC and increasingly adopting syndromic
7 panels. The use of CIDs to detect STEC may improve the timeliness of STEC diagnoses.
8 Prompt and accurate diagnosis of STEC infections, especially those caused by *E. coli* O157, can
9 decrease the risk for serious complications and outcomes, such as renal damage and death.
10 However, for accurate diagnosis of STEC infection, CDC recommends that all stools submitted
11 for routine testing from patients with acute community-acquired diarrhea be simultaneously
12 cultured for *E. coli* O157 and tested with a CIDT that detects Shiga toxins [14]. Some syndromic
13 panels can differentially detect the O157 antigen and also Shiga toxins, which might influence a
14 clinical laboratory's decision to drop culture methods. Specimens that only detect Shiga toxin are
15 reported as STEC-positive; however, reflex culture should be attempted to confirm that the
16 organism producing the toxin is *E. coli*; some species of *Shigella* occasionally produce Shiga
17 toxin [16].
18
19 Adoption of syndromic panels also changed the practices among clinical laboratories testing for
20 parasitic pathogens. By 2017, nearly a quarter of laboratories used a syndromic panel to detect
21 *Cryptosporidium*. By 2019, most laboratories used a syndromic panel routinely to test for
22

1 *Cyclospora*.

2 Conventional diagnostic testing using culture and microscopy might rely on the clinician to
3 choose the correct test, might be sequential, and typically tests for one pathogen at a time [17].
4 Many bacteria can be difficult to culture, and syndromic panels, which are more sensitive and
5 test for multiple pathogens from the same specimen, can decrease turnaround time for patient
6 diagnosis. Adoption of CIDs might also benefit clinical laboratories by decreasing the time and
7 skill needed for pathogen detection. However, culture is still needed for diagnosis of
8 antimicrobial resistant bacterial infections. As the number of clinical laboratories using CIDs
9 increased, the percentage performing reflex culture decreased, and submission of isolates to
10 SPHLs was replaced by submission of stool specimens. As a result, the burden of recovering a
11 bacterial isolate has progressively fallen upon SPHLs, which lack resources to fully absorb this
12 additional testing [6].

13
14 The recovery of isolates by culture, whether by clinical or public health laboratories, remains an
15 essential component of public health efforts to monitor trends and to detect and respond to
16 outbreaks [18]. Public health laboratories have transitioned to using WGS for subtyping enteric
17 pathogens; this method provides better discriminatory power and precision than PFGE for
18 identifying related isolates, and has improved outbreak investigations [19]. However, current
19 WGS technology relies on the ability to recover isolates [11]. We found that the percentage of
20 laboratories in FoodNet sites submitting either specimens or isolates to the SPHL increased from
21 2015 to 2019 for pathogens except STEC, which decreased slightly. This might be partly due to
22 recognition of legal requirements. In 2015, a review of state legal requirements found that 47
23 states had disease reporting laws for at least one enteric pathogen, requiring clinical laboratories

1 to submit clinical materials to public health laboratories [18]. State regulations varied widely by
2 pathogen; submission of specimen versus isolate was not typically specified. In 2015, all 10
3 FoodNet sites had pathogen specimen submission requirements for at least *Listeria*, *Salmonella*,
4 and STEC.

5
6 Our findings are subject to limitations. First, the clinical laboratories included in the study are
7 those that serve FoodNet's surveillance catchment area and may not represent laboratories
8 nationally. Second, data collection methods differed by site and relied on individual laboratory
9 participation. Third, the number of laboratories using blood culture tests that can detect *Listeria*
10 may be underrepresented because some may incubate blood on site and send likely positives to
11 another facility for isolation. Fourth, the data only describe testing practices and do not consider
12 the number of tests performed by each laboratory. Responses from a small office laboratory have
13 equal weight in our analysis as responses from a major commercial laboratory.

15 **Conclusions**

16 Clinical laboratories have an important role in public health surveillance. They are increasingly
17 using CIDs without reflex culture, which transfers the burden of isolate recovery to under-
18 resourced public health laboratories [20]. Although CIDs offer many advantages, such as
19 simultaneously testing for multiple pathogens from a single specimen, isolates are necessary to
20 conduct WGS, identify pathogen subtypes, determine antimicrobial resistance, detect outbreaks,
21 and help link illnesses to likely sources. These isolate-based analyses are essential to
22 implementing and evaluating public health prevention activities. In the future, advanced
23 laboratory methods, such as metagenomics, may allow for molecular subtyping directly from a

1 patient specimen. Until then, states should consider updating their enteric disease reporting
2 requirements to include submission of isolates or specimens to SPHLs and identify adequate
3 resources and partnerships for isolate recovery.

4 **Acknowledgments**

5 We would like to thank diagnostic laboratories that provided these data. Without their
6 participation, this analysis would not be possible.

7 **Disclaimer**

8 The findings and conclusions in this report are those of the authors and do not necessarily
9 represent the official position of CDC.

10 **Financial support**

11 This work was supported in part by cooperative agreement funding from the Center for Disease
12 Control and Prevention to the Emerging Infections Program, the Epidemiology and Laboratory
13 Capacity for Prevention and Control of Emerging Infectious Diseases program, and the
14 Association of Public Health Laboratories.

15 **Patient consent**

16 This study does not include factors necessitating patient consent.

17 **Potential conflicts of interest**

18 All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of
19 Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the
20 manuscript have been disclosed.

References

1. Marder EP, Cieslak PR, Cronquist AB, et al. Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food and the Effect of Increasing Use of Culture-Independent Diagnostic Tests on Surveillance - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2013-2016. *MMWR Morb Mortal Wkly Rep* **2017**; 66(15): 397-403.
2. Murphy CN, Fowler RC, Iwen PC, Fey PD. Evaluation of the BioFire FilmArray(R) GastrointestinalPanel in a Midwestern Academic Hospital. *Eur J Clin Microbiol Infect Dis* **2017**; 36(4): 747-54.
3. Cronquist AB, Mody RK, Atkinson R, et al. Impacts of culture-independent diagnostic practices on public health surveillance for bacterial enteric pathogens. *Clin Infect Dis* **2012**; 54 Suppl 5: S432-9.
4. Iwamoto M, Huang JY, Cronquist AB, et al. Bacterial enteric infections detected by culture-independent diagnostic tests--FoodNet, United States, 2012-2014. *MMWR Morb Mortal Wkly Rep* **2015**; 64(9): 252-7.
5. Clark SD, Sidlak M, Mathers AJ, Poulter M, Platts-Mills JA. Clinical Yield of a Molecular Diagnostic Panel for Enteric Pathogens in Adult Outpatients With Diarrhea and Validation of Guidelines-Based Criteria for Testing. *Open Forum Infect Dis* **2019**; 6(4): ofz162.
6. Langley G, Besser J, Iwamoto M, et al. Effect of Culture-Independent Diagnostic Tests on Future Emerging Infections Program Surveillance. *Emerg Infect Dis* **2015**; 21(9): 1582-8.
7. Binnicker MJ. Multiplex Molecular Panels for Diagnosis of Gastrointestinal Infection: Performance, Result Interpretation, and Cost-Effectiveness. *J Clin Microbiol* **2015**; 53(12): 3723-8.
8. Huang JY, Henao OL, Griffin PM, et al. Infection with Pathogens Transmitted Commonly Through Food and the Effect of Increasing Use of Culture-Independent Diagnostic Tests on Surveillance--Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2012-2015. *MMWR Morb Mortal Wkly Rep* **2016**; 65(14): 368-71.
9. Marder Mph EP, Griffin PM, Cieslak PR, et al. Preliminary Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2006-2017. *MMWR Morb Mortal Wkly Rep* **2018**; 67(11): 324-8.
10. Tack DM, Marder EP, Griffin PM, et al. Preliminary Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2015-2018. *MMWR Morb Mortal Wkly Rep* **2019**; 68(16): 369-73.
11. Tack DM, Ray L, Griffin PM, et al. Preliminary Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2016-2019. *MMWR Morb Mortal Wkly Rep* **2020**; 69(17): 509-14.
12. Plebani M. Clinical laboratory: bigger is not always better. *Diagnosis (Berl)* **2018**; 5(2): 41-6.
13. Voetsch AC, Angulo FJ, Rabatsky-Ehr T, et al. Laboratory practices for stool-specimen culture for bacterial pathogens, including *Escherichia coli* O157:H7, in the FoodNet sites, 1995-2000. *Clin Infect Dis* **2004**; 38 Suppl 3: S190-7.
14. Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of shiga toxin--producing *Escherichia coli* infections by clinical laboratories. *MMWR Recomm Rep* **2009**; 58(RR-12): 1-14.
15. Gould LH, Mody RK, Ong KL, et al. Increased recognition of non-O157 Shiga toxin-producing *Escherichia coli* infections in the United States during 2000-2010: epidemiologic features and comparison with *E. coli* O157 infections. *Foodborne Pathog Dis* **2013**; 10(5): 453-60.
16. Tesh VL, O'Brien AD. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. *Mol Microbiol* **1991**; 5(8): 1817-22.

- 1 17. Goldenberg SD, Bacelar M, Brazier P, Bisnauthsing K, Edgeworth JD. A cost benefit analysis of
2 the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in
3 hospitalised patients. *J Infect* **2015**; 70(5): 504-11.
- 4 18. Laboratories AoPH. State legal requirements for submission of isolates and other clinical
5 materials by clinical laboratories: a review of state approaches. Association of Public Health
6 Laboratories **2015**.
- 7 19. Kubota KA, Wolfgang WJ, Baker DJ, et al. PulseNet and the Changing Paradigm of Laboratory-
8 Based Surveillance for Foodborne Diseases. *Public Health Rep* **2019**; 134(2_suppl): 22S-8S.
- 9 20. Imdad A, Retzer F, Thomas LS, et al. Impact of Culture-Independent Diagnostic Testing on
10 Recovery of Enteric Bacterial Infections. *Clin Infect Dis* **2018**; 66(12): 1892-8.

Table 1. Number and percentage of clinical laboratories testing for surveyed pathogens on site by year and pathogen — Foodborne Diseases Active Surveillance Network, 2012–2019

Pathogen	Year									
	2012		2013		2014		2015		2016	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
<u>Bacteria</u>										
<i>Campylobacter</i>	452	(67)	446	(67)	444	(67)	417	(61)	412	(59)
<i>Listeria</i> *	213	(32)	n/a		n/a		n/a		n/a	
<i>Salmonella</i>	460	(68)	454	(68)	453	(68)	427	(62)	421	(60)
<i>Shigella</i>	460	(68)	453	(68)	452	(68)	427	(62)	421	(60)
STEC†	406	(60)	395	(59)	393	(59)	387	(56)	386	(55)
<i>Vibrio</i>	322	(48)	322	(48)	321	(48)	302	(44)	309	(44)
<i>Yersinia</i>	370	(55)	368	(55)	367	(55)	336	(49)	336	(48)
<u>Parasites</u>										
<i>Cryptosporidium</i> *	252	(37)	251	(38)	251	(38)	252	(37)	261	(37)
<i>Cyclospora</i> *	n/a		n/a		n/a		n/a		n/a	
Laboratories §	673		664		664		687		699	

*Data are unavailable for years in which the pathogen was not included in the survey: *Listeria* (2013–2017), *Cryptosporidium* (2018–2019), *Cyclospora* (2012–2017)

†Shiga toxin-producing *Escherichia coli*

§Diagnostic laboratories for which data was provided

Figure Legends


Figure 1. Percentage of laboratories using culture-based tests only, culture-based tests and culture-independent diagnostic tests (CIDTs), or CIDT only, by pathogen, year, and test type — Foodborne Diseases Active Surveillance Network, 2012–2019

■ Culture only ■ Culture and CIDT ■ CIDT only

Figure 2. Number of laboratories using antigen-based tests, syndromic panels, antigen-based tests and syndromic panels, and laboratory-developed tests to detect *Campylobacter* and Shiga toxin-producing *Escherichia coli* (STEC), by pathogen, year, and test type — Foodborne Diseases Active Surveillance Network, 2012–2019

— Antigen-based test - - - Syndromic panel Antigen-based test and syndromic panel — • — Laboratory-developed test

Figure 1. Percentage of laboratories using culture-based tests only, culture-based tests and culture-independent diagnostic tests (CIDTs), or CIDT only, by pathogen, year, and test type — Foodborne Diseases Active Surveillance Network, 2012–2019



Abbreviations: N = number of laboratories testing for pathogen

**Listeria* was not included in the survey during 2013–2017.

Figure 1
197x234 mm (x DPI)

Figure 2. Number of laboratories using antigen-based tests, syndromic panels, antigen-based tests and syndromic panels, and laboratory-developed tests to detect *Campylobacter* and Shiga toxin-producing *Escherichia coli* (STEC), by pathogen, year, and test type — Foodborne Diseases Active Surveillance Network, 2012–2019





Figure 2
173x104 mm (x DPI)

Figure 3. Percentage of laboratories* that performed reflex culture on site after pathogen detection by culture-independent diagnostic test, by pathogen—Foodborne Diseases Active Surveillance Network, 2015 and 2019




Abbreviations: N = number of laboratories using a CIDT test

*Among laboratories with information available. In 2015, data on reflex culture was unknown for 16 laboratories for *Campylobacter*, 5 for *Salmonella*, 4 for *Shigella*, 1 for *Vibrio*, and 0 for *Yersinia*. In 2019, unknown for 1 laboratory for *Campylobacter*, 3 for *Salmonella*, 3 for *Shigella*, 1 for *Vibrio*, and 0 for *Yersinia*.

Figure 3
176x140 mm (x DPI)

Figure 4. Percentage of laboratories* that routinely sent broth, stool, isolates, or nothing to a state public health laboratory in 2015 compared with 2019, by pathogen — Foodborne Diseases Active Surveillance Network



Abbreviations: N = number of laboratories testing for pathogen

*Percentage among laboratories when known. Some laboratories routinely submit multiple specimens. In 2015, data on specimen submission was unknown for 69 laboratories for *Campylobacter*, 74 for STEC, 74 for *Salmonella*, 73 for *Shigella*, 47 for *Vibrio*, and 55 for *Yersinia*. In 2019, unknown for 8 laboratories for *Campylobacter*, 12 for STEC, 9 for *Salmonella*, 21 for *Shigella*, 14 for *Vibrio*, and 11 for *Yersinia*.

[†]Shiga toxin-producing *Escherichia coli*.

Figure 4
239x205 mm (x DPI)